Given the lack of research elucidating the effect of anthraquinone in CRC, this study aim to discover novel potential inhibitors based on anthraquinones from Morinda citrifolia through the deployment of ligand-based protein docking for β-catenin, MDM2-p53 and KRAS. This evidence concerns the gene TP53 and colorectal carcinoma.